01 January 2022: Clinical Research
A Statistical Prediction Model for Survival After Kidney Transplantation from Deceased Donors
Jia-shan Pan AE* , Yi-ding Chen BC* , Han-dong Ding B , Tian-chi Lan B , Fei Zhang B , Jin-biao Zhong A* , Gui-yi Liao AF*DOI: 10.12659/MSM.933559
Med Sci Monit 2022; 28:e933559
Table 1 Demographics and clinical characteristics of the death and survival groups.
| Characteristics | Death group | Survival group | Total (%) |
|---|---|---|---|
| n=15 (9.9%) | n=136 (90.1%) | n=151 (100%) | |
| Donor age (years) | |||
| >50 | 4 (2.6%) | 69 (45.7%) | 73 (48.3%) |
| ≤50 | 11 (7.3%) | 67 (44.4%) | 78 (51.7%) |
| Recipient age (years) | |||
| >53 | 4 (2.6%) | 9 (6.0%) | 13 (8.6%) |
| ≤53 | 11 (7.3%) | 127 (84.1%) | 138 (91.4%) |
| Creatinine | |||
| >1000.3 | 9 (6.0%) | 61 (40.4%) | 70 (46.4%) |
| ≤1000.3 | 6 (4.0%) | 75 (49.6%) | 81 (53.6%) |
| Urea | |||
| >21.8 | 8 (5.3%) | 59 (39.1%) | 67 (44.4%) |
| ≤21.8 | 7 (4.6%) | 77 (51.0%) | 84 (55.6%) |
| UA | |||
| >293 | 14 (9.3%) | 108 (71.5%) | 122 (80.8%) |
| ≤293 | 1 (0.7%) | 28 (18.5%) | 29 (19.2%) |
| ALT | |||
| >28 | 4 (2.6%) | 62 (41.1%) | 66 (43.7%) |
| ≤28 | 11 (7.3) | 74 (49.0%) | 85 (56.3%) |
| AST | |||
| >14 | 8 (5.3%) | 91 (60.3%) | 99 (65.6%) |
| ≤14 | 7 (4.6%) | 45 (29.8%) | 52 (34.4%) |
| Tbil | |||
| >8.2 | 6 (4.0%) | 89 (58.9%) | 95 (62.9%) |
| ≤8.2 | 9 (6.0%) | 47 (31.1%) | 56 (37.1%) |
| ALP | |||
| >134 | 5 (3.3%) | 27 (17.9%) | 32 (21.2%) |
| ≤134 | 10 (6.6%) | 109 (72.2%) | 119 (78.8%) |
| TP | |||
| >69.6 | 14 (9.3%) | 105 (69.5%) | 119 (78.8%) |
| ≤69.6 | 1 (0.7%) | 31 (20.5%) | 32 (21.2%) |
| ALB | |||
| >50.1 | 1 (0.7%) | 36 (23.8%) | 37 (24.5%) |
| ≤50.1 | 14 (9.3%) | 100 (66.2%) | 114 (75.5%) |
| GLOB | |||
| >26.3 | 13 (8.6%) | 97 (64.2%) | 110 (72.8%) |
| ≤26.3 | 2 ((1.3%) | 39 (25.8%) | 41 (27.2%) |
| A/G | |||
| >1.48 | 8 (5.3%) | 87 (57.6%) | 95 (62.9%) |
| ≤1.48 | 7 (4.6%) | 49 (32.5%) | 56 (37.1%) |
| K | |||
| >4.62 | 10 (6.6%) | 68 (45.0%) | 78 (51.7%) |
| ≤4.62 | 5 (3.3%) | 68 (45.0%) | 73 (48.3%) |
| Na | |||
| >142.6 | 8 (5.3%) | 30 (19.9%) | 38 (25.2%) |
| ≤142.6 | 7 (4.6%) | 106 (70.2%) | 113 (74.8%) |
| Cl | |||
| >101 | 5 (3.3%) | 45 (29.8%) | 50 (33.1%) |
| ≤101 | 10 (6.6%) | 91 (60.3%) | 101 (66.9%) |
| HCO | |||
| >21.1 | 7 (4.6%) | 91 (60.3%) | 98 (64.9%) |
| ≤21.1 | 8 (5.3%) | 45 (29.8%) | 53 (35.1%) |
| FBG | |||
| >4.97 | 11 (7.3%) | 86 (67%) | 97 (64.2%) |
| ≤4.97 | 4 (2.6%) | 50 (33.1%) | 54 (35.8%) |
| WBC (×10) | |||
| >5.63 | 12 (7.9%) | 94 (62.3%) | 106 (70.2%) |
| ≤5.63 | 3 (2.0%) | 42 (27.8%) | 45 (29.8%) |
| Neut ratio (%) | |||
| >75.54 | 1 (0.7%) | 35 (23.2%) | 36 (23.8%) |
| ≤75.54 | 14 (9.3%) | 101 (66.9%) | 115 (76.2%) |
| Lymph ratio (%) | |||
| >19.52 | 11 (7.3%) | 79 (52.3%) | 90 (60.0%) |
| ≤19.52 | 4 (2.6%) | 57 (37.7%) | 61 (40.4%) |
| Neut (×10) | |||
| >3.5 | 13 (8.7%) | 93 (61.6%) | 106 (70.2%) |
| ≤3.5 | 2 (1.3%) | 43 (28.5%) | 45 (29.8%) |
| Lymph (×10) | |||
| >1.16 | 12 (7.9%) | 89 (58.9%) | 101 (66.9%) |
| ≤1.16 | 3 (2.0%) | 47 (31.1%) | 50 (33.1%) |
| Mono (×10) | |||
| >0.32 | 8 (5.3%) | 82 (54.3%) | 90 (59.6%) |
| ≤0.32 | 7 (4.6%) | 54 (35.8%) | 61 (40.4%) |
| Eo (×10) | |||
| >0.19 | 8 (5.3%) | 51 (33.8%) | 59 (39.1%) |
| ≤0.19 | 7 (4.6%) | 85 (56.3%) | 92 (60.9%) |
| Baso (×10) | |||
| >0.03 | 3 (2.0%) | 26 (17.2%) | 29 (19.2%) |
| ≤0.03 | 12 (7.9%) | 110 (72.8%) | 122 (80.8%) |
| RBC (×10) | |||
| >4.59 | 4 (2.6%) | 13 (8.6%) | 17 (11.3%) |
| ≤4.59 | 11 (7.3%) | 123 (81.5%) | 134 (88.7%) |
| Hb | |||
| >138 | 3 (2.0%) | 15 (9.9%) | 18 (11.9%) |
| ≤138 | 12 (7.9%) | 121 (80.1%) | 133 (88.1%) |
| PLT (×10) | |||
| >128 | 10 (6.7%) | 117 (77.5%) | 127 (84.1%) |
| ≤128 | 5 (3.3%) | 19 (12.6%) | 24 (15.9%) |
| BMI | |||
| >22.6 | 9 (6.0%) | 60 (39.7%) | 69 (45.7%) |
| ≤22.6 | 6 (4.0%) | 76 (50.3%) | 82 (54.3%) |
| Dialysis time (months) | |||
| >36 | 9 (6.0%) | 69 (45.7%) | 78 (51.7%) |
| ≤36 | 6 (4.0%) | 67 (44.4%) | 73 (48.3%) |
| Sex | |||
| Male | 14 (9.3%) | 119 (78.8%) | 133 (88.1%) |
| Female | 1 (0.7%) | 17 (11.3%) | 18 (11.9%) |
| DM | |||
| Yes | 1 (0.7%) | 8 (5.3%) | 9 (6.0%) |
| No | 14 (9.3%) | 128 (84.8%) | 142 (94.0%) |
| HBP | |||
| Yes | 12 (8.0%) | 95 (62.9%) | 107 (70.9%) |
| No | 3 (2.0%) | 41 (27.2%) | 44 (29.1%) |
| Distance (km) | |||
| 0~50 | 3 (2.0%) | 35 (23.2%) | 38 (25.2%) |
| 51~200 | 10 (6.6%) | 70 (46.4%) | 80 (53.0%) |
| 201~300 | 2 (1.3%) | 15 (9.9%) | 17 (11.3%) |
| >300 | 0 (0.0%) | 16 (10.6%) | 16 (10.6%) |
| UV – uric acid; FBG – fasting blood-glucose; Neut – neutrophil; Tbil – total bilirubin; ALB – albumin; GLOB – globulin; A/G – ratio of albumin to globulin; Mono – neutrophile percent; Lymph – monocytes; EO – eosinophilic; Baso – basophilic granulocyte; HB – hemoglobin; HBP – high blood pressure; pt-DM – pre-transplant diabetes mellitus. | |||